Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses

Schmiedeberg, Kristin; Vuilleumier, Nicolas; Pagano, Sabrina; Albrich, Werner C; Ludewig, Burkhard; Kempis, Johannes von; Rubbert-Roth, Andrea

doi:10.1016/S2665-9913(21)00328-3

Scientific article

English

Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses

ContributorsSchmiedeberg, Kristin; Vuilleumier, Nicolas; Pagano, Sabrina

; Albrich, Werner C; Ludewig, Burkhard; Kempis, Johannes von; Rubbert-Roth, Andrea

Published inThe Lancet. Rheumatology

First online date2021-10-26

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Auto-immunité, inflammation et athérosclérose (270)

Citation (ISO format)

SCHMIEDEBERG, Kristin et al. Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. In: The Lancet. Rheumatology, 2021. doi: 10.1016/S2665-9913(21)00328-3

Article (Published version)

Appendix

Identifiers

PID : unige:157632
DOI : 10.1016/S2665-9913(21)00328-3
PMID : 34723209
PMCID : PMC8547803

Additional URL for this publicationhttps://www.sciencedirect.com/science/article/pii/S2665991321003283

Journal ISSN2665-9913

245views

203downloads

Creation17/11/2021 14:36:00

First validation17/11/2021 14:36:00

Update23/01/2025 11:25:59

Status update23/01/2025 11:25:59

Last indexation23/01/2025 11:34:13

Archive ouverte UNIGE

Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses

Technical informations